Table 2.
shows baseline characteristics of enrolled patients in included studies
| Study ID | Arm | Demographics | Surgical Risk | Comorbidities | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample Size | Age | Male sex (%) | EURO score | STS score | CAD | Previous PCI | HTN | Cerebral Vascular Disease | Peripheral Vascular Disease | Diabetes Mellitus | ||
| I. Randomized Controlled Trials | ||||||||||||
| PARTNER II trial [8] | SAVR | 1021 | 81.7 ± 6.7 | 560 (54.8) | NA | 5.8 ± 1.9 | 679 (66.5) | 282 (27.6) | NA | 317 (31) | 336 (32.9) | 349 (34.2) |
| TAVR | 1011 | 81.5 ± 6.7 | 548 (54.2) | NA | 5.8 ± 2.1 | 700 (69.2) | 274 (27.1) | NA | 325 (32.1) | 282 (27.9) | 381 (37.7) | |
| STACATTO trial [11] | SAVR | 36 | 82 ± 4.4 | 12 (33.3) | 10.3 ± 5.8 | 3.4 ± 1.2 | NA | NA | NA | 1 (2.8) | 3 (8.3) | 3 (8.3) |
| TAVR-TA | 34 | 80 ± 3.6 | 9 (26.5) | 9.4 ± 3.9 | 3.1 ± 1.5 | NA | NA | NA | 1 (2.9) | 2 (5.9) | 1 (2.9) | |
| NOTION trial [9] | SAVR | 135 | 79 ± 4.7 | 71 (52.6) | 8.9 ± 5.5 | 3.1 ± 1.7 | 6 (4.4) | 12 (8.9) | 103 (76.3) | 22 (16.3) | 9 (6.7) | 28 (20.7) |
| TAVR | 145 | 79.2 ± 4.9 | 78 (53.8) | 8.4 ± 4 | 2.9 ± 1.6 | 8 (5.5) | 11 (7.6) | 103 (71) | 24 (16.6) | 6 (4.1) | 26 (17.9) | |
| US PIVOTAL trial [10] | SAVR | 359 | 83.3 ± 6.3 | 188 (52.4) | 18.8 ± 13.2 | 7.5 ± 3.3 | 273 (76) | 135 (37.6) | 345 (96.1) | NA | 150 (42) | 162 (45.1) |
| TAVR | 391 | 83.2 ± 7.1 | 207 (52.9) | 17.7 ± 13 | 7.3 ± 3.0 | 295 (75.4) | 134 (34.3) | 372 (95.1) | NA | 159 (41) | 136 (34.8) | |
| II. Observational (Prospective and Retrospective Studies) | ||||||||||||
| OBSERVENT Study [12] | SAVR | 1383 | 72 ± 9 | 768 (55.5) | 6.1 ± 7.1 | NA | NA | 95 (6.8) | NA | NA | 176 (12.7) | 346 (25) |
| TAVR-TA | 602 | 82 ± 6 | 243 (40.4) | 15.2 ± 14.3 | NA | NA | 151 (25.1) | NA | NA | 114 (18.9) | 145 (24.1) | |
| TAVR-TF | 123 | 82 ± 7 | 54 (43.9) | 14.7 ± 11.3 | NA | NA | 31 (25.2) | NA | NA | 47 (38.2) | 34 (27.6) | |
| Osnabrugge et al. 2012 [21] | SAVR | 42a | 79.3 ± 5.5 | 22 (52.4) | 12.5 ± 6.4 | NA | 20 (47.6) | NA | NA | 2 (4.8) | 4 (9.5) | 8 (19) |
| TAVR | 42a | 78.8 ± 6.6 | 21 (50) | 12.9 ± 6.8 | NA | 20 (47.6) | NA | NA | 2 (4.8) | 3 (7.1) | 11 (26.2) | |
| Piazza et al. 2013 [22] | SAVR | 405 | 79.4 ± 4.8 | 179 (44.1) | 17.5 ± 12.1 | NA | 96 (57.8) | NA | 286 (81.7) | 30 (7.4) | 41 (10.1) | 98 (25.7) |
| TAVR | 405 | 79.9 ± 6 | 175 (43.2) | 17.1 ± 10.7 | NA | 94 (56.6) | NA | 301 (86) | 40 (9.9) | 33 (8.2) | 111 (27.4) | |
| Schymik et al. 2015 [24] | SAVR | 216 | 78.2 ± 4.6 | 51.4% | 8.8 ± 2.8 | NA | 48.1% | NA | NA | NA | 6.9% | NA |
| TAVR | 216 | 78.3 ± 5.2 | 46.3% | 8.7 ± 2.7 | NA | 48.1% | NA | NA | NA | 5.1% | NA | |
| Castrodeza et al. 2016 [18] | SAVR | 70 | 78 ± 5.6 | 34 (48.6) | 9.3 ± 3.9 | 4.3 ± 2.4 | NA | NA | 51 (72.9) | NA | NA | 18 (25.7%) |
| TAVR | 70 | 79 ± 7.7 | 36 (51.4) | 9.4 ± 3.8 | 4.6 ± 2.1 | NA | NA | 45 (64.3) | NA | NA | 26 (37.1%) | |
| Latib et al. 2012 [19] | SAVR | 111 | 79.4 ± 3 | 49 (44.1) | 24.4 ± 13.4 | 4.6 ± 2.6 | 51 (45.9) | NA | 77 (69.4) | 20 (18) | 38 (34.2) | 24 (21.6) |
| TAVR | 111 | 80.5 ± 6.9 | 49 (44.1) | 23.2 ± 15.1 | 4.6 ± 2.3 | 44 (39.6) | NA | 78 (70.3) | 16 (14.4) | 29 (26.1) | 21 (18.9) | |
| Möllmann et al. 2016 [20] | SAVR | 9899 | 68.1 ± 11 | 60.4% | NA | NA | 21.1% | 8.9% | NA | 5% | 4.5% | 24.1% |
| TAVR-TF | 7620 | 81.2 ± 6.1 | 44.5% | NA | NA | 55% | 29.6% | NA | 7.8% | 14.4% | 33.6% | |
| TAVR-TA | 2821 | 80.3 ± 6.6 | 52.4% | NA | NA | 60.8% | 30.4% | NA | 9.2% | 32% | 33.4% | |
aFollowing propensity score matching. The presented data are either frequency (%) or mean ± standard deviation, unless stated otherwise
Abbreviations: CAD Coronary artery disease, HTN Hypertension, NA Not Available, PCI Percutaneous coronary intervention, SAVR Surgical aortic valve replacement, STS Society of Thoracic Surgeons, TAVR Transcatheter aortic valve replacement, TA Trans-Apical, TF Trans-Femoral